News

Too many lung cancer patients don't get all the biomarker testing they should have before beginning treatment. Dr. Adam Fox wants to change that.

A Hollings immunologist will use an American Cancer Society Research Scholar Grant to study ways to make colorectal cancer more susceptible to immunotherapy.

Exhibit showcasing history, mission and achievements of The Duke Endowment, private foundation that funds important work at MUSC and elsewhere, comes to campus.

An MUSC Hollings Cancer Center team describes how the bacteria Porphyromonas gingivalis connects to chemotherapy resistance.

MUSC scientists who study cannabis answer questions about delta-8 THC, a psychoactive substance that’s growing in popularity.

Polyploid giant cancer cells, which are monstrously oversized and contain multiple nuclei, could be culprits in disease recurrence after cancer therapy.

A new study from Hollings researchers suggests a dual approach for targeting pancreatic cancer.

External evaluation of MUSC’s telestroke program confirms that stroke center certification and stroke coordinators improve stroke-care metrics.

A new dedicated phase I clinical trials unit at Hollings means more and different types of clinical trials will be available to cancer patients.

A new study is the first in the U.S. to show that an available generic drug could help people stop using e-cigarettes.